文献速递银屑病与炎症性皮肤病

固定复方丙酸卤倍他索0.01%/他扎罗汀0.045%洗剂长期治疗中重度斑块状银屑病的3期开放标签研究

Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-02-07

本研究为为期1年的多中心开放标签研究,纳入555例中重度斑块状银屑病成人患者,评估丙酸卤倍他索(HP)0.01%/他扎罗汀(TAZ)0.045%固定复方洗剂的长期安全性、疗效及疗效维持。550例有基线后安全性数据的受试者中318例(57.8%)治疗成功,最常见治疗相关不良事件为用药部位皮炎、瘙痒、疼痛和刺激。结论认为该复方洗剂可维持疗效且耐受性良好,支持其用于长期治疗和管理。

要点

  • HP/TAZ复方洗剂在1年研究中57.8%患者达到治疗成功。
  • 治疗成功者中超过半数停药后4周以上无需再治疗。
  • 最常见不良事件为用药部位皮炎、瘙痒、疼痛和刺激。

核心结论

  • 固定复方HP/TAZ洗剂可维持疗效,耐受性和安全性良好,支持其用于中重度斑块状银屑病的长期治疗和管理。

研究设计与样本

  • 为期1年的多中心开放标签研究,纳入555例基线IGA评分为3(中度)或4(重度)且BSA为3-12%的成人银屑病患者。
  • HP/TAZ每日一次给药8周,之后根据治疗成功(IGA 0或1)按需间歇给药,间隔4周,最长1年;最大连续暴露24周。

主要发现

  • 550例有基线后安全性数据的受试者中,318例(57.8%)在研究期间达到治疗成功。
  • 治疗成功者中54.4%在最初8周内达到治疗成功;超过半数(55.3%)超过4周无需再治疗,6.6%无需任何再治疗。
  • 入组满52周的受试者中,77.5%在治疗中维持BSA≤5%。
  • 研究期间瘙痒、干燥和灼烧/刺痛严重程度显著改善。
  • 最常见治疗相关不良事件为用药部位皮炎、瘙痒、疼痛和刺激等应用部位反应。

关键数值与推荐

  • 基线入组标准为IGA评分3(中度)或4(重度)且BSA为3-12%。
  • 治疗成功定义为IGA评分为0(清除)或1(几乎清除)。

临床怎么用

  • 对于中重度斑块状银屑病成人患者,可考虑HP/TAZ复方洗剂每日一次8周后按需间歇长期治疗。
  • 长期治疗中需关注用药部位皮炎、瘙痒、疼痛和刺激等不良反应。

局限性

  • 本研究为开放标签设计,未设对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment. To mitigate adverse cutaneous reactions observed with monotherapy, a fixed- combination HP 0.01%/TAZ 0.045% lotion has been developed for the treatment of plaque psoriasis in adults. OBJECTIVES: To investigate the long-term safety, efficacy and maintenance of response with HP/TAZ lotion. METHODS: This was a 1-year, multicentre, open-label study in 555 adults with psoriasis [Investigator's Global Assessment (IGA) score of 3 ('moderate') or 4 ('severe') and body surface area (BSA) of 3-12% at baseline]. HP/TAZ was administered once daily for 8 weeks and then intermittently as needed in 4-week intervals for up to 1 year based on achievement of treatment success [IGA score of 0 ('clear') or 1 ('almost clear')]. Maximum continuous exposure was 24 weeks. RESULTS: Of 550 participants with postbaseline safety data, 318 (57.8%) achieved treatment success during the study. Of those, 54.4% achieved treatment success within the first 8 weeks; retreatment was not required for >4 weeks in over half (55.3%), and 6.6% did not require any retreatment. Among participants enrolled for the full 52 weeks, 77.5% maintained BSA ≤5% on treatment. There were marked improvements in severity of itching, dryness and burning/stinging over the study course. The most common treatment-related adverse events were application site reactions of dermatitis, pruritus, pain and irritation. CONCLUSIONS: Fixed-combination HP/TAZ lotion provided maintained efficacy with a favourable tolerability and safety profile, supporting its use for the long-term treatment and management of moderate-to-severe plaque psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lebwohl MG, Stein Gold L, Papp K, et al. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. J Eur Acad Dermatol Venereol. 2021. PMID: 33428282. doi:10.1111/jdv.17113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。